Cancer Treatment Gets Cheaper: Huge Price Drop for Life-Saving Drugs from Nov 9
NPPA directive leads to massive price cuts for cancer medicines in India, including lung and prostate cancer drugs. Find out the new rates.
In a move that promises significant financial relief for thousands of patients across the country, the prices of several critical cancer drugs price reduction measures will come into effect starting November 9. This follows a directive from the National Pharmaceutical Pricing Authority (NPPA), aimed at making life-saving treatments more accessible to the common man.
Massive Price Cuts Across Major Formulations
Pharmaceutical companies are revising their Maximum Retail Prices (MRP) in compliance with an order issued by the NPPA on October 17. The price drops are particularly steep for medicines used to treat lung, kidney, colorectal, and prostate cancers.
The impact of these reductions is stark when looking at specific injections and tablets:
- BevakALP 100 mg injection: The price is plummeting from Rs 10,500 to Rs 4,523, marking a 57 per cent decrease.
- BevakALP 400 mg injection: In one of the most significant drops, the cost will fall from Rs 42,000 to Rs 13,136, a reduction of 69 per cent.
- Pemotide 500 mg injection: This will see a price cut from Rs 6,985 down to Rs 2,597.65.
- Erlocip 150 mg (Cipla): Used for lung cancer treatment, a pack of 30 tablets will now cost Rs 3,448, down from Rs 9,798.99.
- Xbira 250 mg: Used for prostate cancer, 120 tablets will now be available for Rs 11,048, reduced from Rs 22,120.
However, it is important to note that not all medications are affected; the prices for Gazyva and Actemra injections will remain unchanged.
A Victory for Humanity
Medical professionals have hailed the government's decision to cap trade margins to lower the cost of these essential medicines. Dr. Ashok Kumar Vaid, Chairman of Medical Oncology and Haematology at Medanta The Medicity, expressed his strong support for the move.
"We wholeheartedly welcome the Government of India’s initiative to make life-saving cancer medicines more affordable through the capping of trade margins, a progressive step towards accessible healthcare for all. Saving human lives is far more important than commercial profits, and every step that reduces the financial burden on cancer patients is a victory for humanity," stated Dr. Vaid.
The Bigger Picture: Will Total Hospital Bills Drop?
While the reduction in the MRP of drugs will certainly lower out-of-pocket expenses for patients purchasing medicines, a critical question remains regarding the overall cost of treatment. Since cancer care involves not just medication, but also expensive diagnostic tests, administration fees, and various miscellaneous hospital charges, it remains to be seen if hospitals will pass on the overall cost benefits to the patients.